TITLE

COMMENTARY: Enoxaparin was more effective than unfractionated heparin in STEMI, regardless of type of fibrinolytic agent used

AUTHOR(S)
Bates, Eric R.
PUB. DATE
November 2007
SOURCE
ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p63
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author reflects upon the findings of a study, that investigated the effectiveness of enoxaparin, in comparison with unfractionated heparin (UFH), for patients with ST-elevation myocardial infarction (STEMI). He states that the study suggests the use of anticoagulation for patients until hospital discharge. He suspects that the benefits of enoxaparin over UFH may have resulted from the longer duration of therapy. He also points that bleeding rates increased with enoxaparin.
ACCESSION #
28019866

 

Related Articles

  • Benefits of long-term post-MI anticoagulation outweigh the costs.  // Modern Medicine;Jul95, Vol. 63 Issue 7, p49 

    Presents an abstract of the articles `Costs and effects of long-term oral anticoagulant treatment after myocardial infarction,' by P.F.M. van Bergen, J.J.C. Jonker et al, published in the March 22-29, 1995 issue of the `Journal of the American Medical Association,' and `Economics and efficacy in...

  • Oral anticoagulants--the totem and the taboo. Breckenridge, A. // British Medical Journal;2/21/1976, Vol. 1 Issue 6007, p419 

    Investigates the efficacy of oral anticoagulants. Controversy on the use of anticoagulants in acute myocardial infarction; Conduction of a clinical trial on the effectiveness of anticoagulants; Conclusion that anticoagulants is of no benefits as a treatment to diseases.

  • Enoxaparin was more effective than unfractionated heparin in STEMI, regardless of type of fibrinolytic agent used.  // ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p63 

    The article offers information on a study that investigates the effectiveness of enoxaparin, in comparison with unfractionated heparin (UFH), for patients with ST-elevation myocardial infarction (STEMI), irrespective of the type of fibrinolytic agent used. It describes the method and patients'...

  • Can BRIGHT Restore the Glow of Bivalirudin? Cavender, Matthew A.; Faxon, David P. // JAMA: Journal of the American Medical Association;4/7/2015, Vol. 313 Issue 13, p1323 

    The authors focus on the results of the Bivalirudin in Acute Myocardial Infarction Versus Heparin and Glycoprotein IIb/IIIa Inhibitors (GPI) Plus Heparin Trial (BRIGHT) conducted by Y. Han and colleagues. The trial studies direct thrombin inhibitor bivalirudin in patients undergoing percutaneous...

  • Heparin for acute MI is not necessarily the best course.  // Modern Medicine;Jul98, Vol. 66 Issue 7, p29 

    Presents an abstract of the article `Use and Effectiveness of Intravenous Heparin Therapy for Treatment of Acute Myocardial Infarction in the Elderly,' by H. M. Krumholz, J. Hennen, et al from the `Journal of American College Cardiol' dated April 1998.

  • COMMENTARY: Fondaparinux reduced death or reinfarction in acute ST-segment elevation myocardial infarction. Borzak, Steven // ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p29 

    The article comments on the study related to the use of the drug fondaparinux to treat patients with acute ST-segment elevation myocardial infarction (STEMI). In the study fondaparinux was found useful in reducing death. These trials support the use of anticoagulant therapy in patients with...

  • Clot-busters for `brain attacks'. E.B. // Medical Update;Mar97, Vol. 20 Issue 9, p4 

    Examines the use of clot-dissolving drugs in treating heart attack patients. Problems faced by physicians in treating stroke; Seeming neglect of physicians on using an aggressive approach to treating stroke.

  • Antithrombotic drug called useful adjunct to streptokinase.  // Geriatrics;May94, Vol. 49 Issue 5, p20 

    Reports on a medical trial using an antithrombotic agent called Hirudin in the treatment of patients with acute myocardial infarction (MI). Usefulness as an adjunct to streptokinase; Inhibition of both free and clot-bound thrombin; Trend toward lower rates of mortality and clinical events.

  • Anticoagulant Therapy in the Relatively Young Male with Myocardial Infarction. Myers Jr., John E.; Bauer, Frank L. // Annals of Internal Medicine;Nov61, Vol. 55 Issue 5, p760 

    Investigates anticoagulant therapy for acute myocardial infarction in young male patients. Comparison of anticoagulant and non-anticoagulant therapy; Rationale for anticoagulant therapy; Mortality rates after therapy.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics